- Home
- UMAC vs CDXS Comparison
UMAC vs CDXS Comparison
Compare UMAC & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- CDXS
- Stock Information
- Founded
- UMAC 2019
- CDXS 2002
- Country
- UMAC United States
- CDXS United States
- Employees
- UMAC N/A
- CDXS N/A
- Industry
- UMAC
- CDXS Major Chemicals
- Sector
- UMAC
- CDXS Industrials
- Exchange
- UMAC Nasdaq
- CDXS Nasdaq
- Market Cap
- UMAC 267.7M
- CDXS 216.6M
- IPO Year
- UMAC 2024
- CDXS 2010
- Fundamental
- Price
- UMAC $15.64
- CDXS $2.64
- Analyst Decision
- UMAC Strong Buy
- CDXS Buy
- Analyst Count
- UMAC 3
- CDXS 2
- Target Price
- UMAC $19.33
- CDXS $11.00
- AVG Volume (30 Days)
- UMAC 4.0M
- CDXS 517.3K
- Earning Date
- UMAC 11-13-2025
- CDXS 10-30-2025
- Dividend Yield
- UMAC N/A
- CDXS N/A
- EPS Growth
- UMAC N/A
- CDXS N/A
- EPS
- UMAC N/A
- CDXS N/A
- Revenue
- UMAC $7,701,550.00
- CDXS $57,164,000.00
- Revenue This Year
- UMAC $86.94
- CDXS $12.88
- Revenue Next Year
- UMAC $118.95
- CDXS $21.64
- P/E Ratio
- UMAC N/A
- CDXS N/A
- Revenue Growth
- UMAC 279.38
- CDXS N/A
- 52 Week Low
- UMAC $1.28
- CDXS $1.90
- 52 Week High
- UMAC $23.62
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- UMAC 70.43
- CDXS 52.60
- Support Level
- UMAC $15.13
- CDXS $2.51
- Resistance Level
- UMAC $17.48
- CDXS $2.73
- Average True Range (ATR)
- UMAC 1.50
- CDXS 0.11
- MACD
- UMAC 0.23
- CDXS 0.03
- Stochastic Oscillator
- UMAC 76.98
- CDXS 56.80
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.